Abstract-Cardiovascular risk factors, such as diabetes mellitus and central obesity, have been associated with Parkinson disease (PD), but data on blood pressure and PD are lacking. We sought to examine the association of blood pressure and hypertension with the risk of PD among men and women. This study consisted of 7 surveys Several population-based follow-up studies suggest that PD is associated with cardiovascular risk factors, such as diabetes mellitus and central obesity, 3,4 but the association with blood pressure (BP) and hypertension remains to be explored. The pooled data from the Nurses' Health Study and Health Professionals Follow-Up Study show no association of PD with a self-reported hypertension, 5 whereas case-control studies suggest a reduced odds ratio of PD related to a history of hypertension. 6, 7 We have reported previously that cardiovascular risk factors, such as diabetes mellitus, increased body mass index (BMI), and high total cholesterol, are associated with an increased risk of PD. 8 -10 In this study, which is based on national population surveys in Finland (National FINRISK Study), we sought to investigate whether BP and hypertension are associated with the risk of PD among men and women.
P
arkinson disease (PD) is the second most common neurodegenerative disorder after Alzheimer disease. 1 Since the 1990s, epidemiological research has significantly contributed to the understanding of etiology for Alzheimer disease, in which the role of cardiovascular risk factors has been generally recognized. 2 By contrast, influential factors other than age and smoking for PD are largely unknown. 1 Several population-based follow-up studies suggest that PD is associated with cardiovascular risk factors, such as diabetes mellitus and central obesity, 3, 4 but the association with blood pressure (BP) and hypertension remains to be explored. The pooled data from the Nurses' Health Study and Health Professionals Follow-Up Study show no association of PD with a self-reported hypertension, 5 whereas case-control studies suggest a reduced odds ratio of PD related to a history of hypertension. 6, 7 We have reported previously that cardiovascular risk factors, such as diabetes mellitus, increased body mass index (BMI), and high total cholesterol, are associated with an increased risk of PD. 8 -10 In this study, which is based on national population surveys in Finland (National FINRISK Study), we sought to investigate whether BP and hypertension are associated with the risk of PD among men and women.
Methods

Study Population
The National FINRISK Study consisted of population surveys on the risk factors of chronic noncommunicable diseases. 11 By 2002, 7 independent cross-sectional surveys for the FINRISK Study had been completed in 1972, 1977, 1982, 1987, 1992, 1997 , and 2002 on representative samples derived from 6 geographic areas of Finland.
In 1972 and 1977, a sample making up 6.6% of the population born in 1913-1947 was randomly selected. Since 1982, the sampling had been stratified by area, sex, and 10-year age group according to the World Health Organization Multinational Monitoring of Trends and Determinants in Cardiovascular Disease protocol. The surveys included people aged 25 to 64 years until 1992, and subjects aged 65 to 74 years were also included in the surveys conducted in 1997 and 2002. In total, 62 013 subjects were examined in the 7 surveys, with the participation rate varying by year from 66.5% to 95.0%. 11 At baseline, we excluded subjects with PD (nϭ146), stroke (nϭ984), and those with incomplete data on key research variables (nϭ1343), leaving 28 725 men and 30 815 women for the current analysis.
The FINRISK surveys were approved by the ethics committee at the Finnish National Public Health Institute or by the coordinating ethics committee of Helsinki University District. All of the participants provided verbal or written (since 1997) informed consent. All of the surveys were conducted in accordance with the Declaration of Helsinki.
BP Measurements
BP was measured at the study site by specially trained nurses following the World Health Organization Multinational Monitoring of Trends and Determinants in Cardiovascular Disease protocol. 11, 12 The protocol is based on extensive training and quality-control procedure to ensure the validity and reliability of measurements. After at least a 5-minute rest, seated arterial BP (Korotkoff phase V for diastolic pressure) was measured once in surveys conducted in 1972 and 1977, twice in 1982-1997, and 3 times in 2002 using a mercury sphygmomanometer on the subject's right arm. The cuff size was chosen according to arm circumference. BP readings were recorded to the nearest 2 mm Hg. The mean of the first 2 measurements, whenever available, was used in the analysis. 12 Information on the use of antihypertensive agents preceding the survey was collected from subjects during the surveys.
PD Ascertainment
The PD status until December 31, 2006, of all of the participants was determined according to the National Social Insurance Institution register on special reimbursement for drug costs that was started in 1964. 8 -10 In Finland, all of the patients diagnosed with PD are eligible for free drug treatment. By institution regulations, the diagnosis of PD has to be based on medical history and the presence of primary symptoms and signs (tremor, bradykinesia, rigidity, and postural instability) determined by comprehensive clinical assessments. Furthermore, the diagnosis has to be done by a specialist in neurology, and non-PD causes of symptoms must be excluded. Intention tremor, essential tremor, or tremor caused by neuroleptic drugs does not justify drug reimbursement under the regulations. A detailed written statement from the physician in charge of the treatment to verify the clinical course and diagnostic facts is required for the reimbursement. Then, the statement is reviewed by the institution specialists. Only when the diagnosis of PD is independently agreed on by 2 specialists are the patients entitled to receive medications free of charge. The approval date of reimbursement is considered to be the time of PD onset, which means that the true onset date is slightly earlier than the date that we defined here. It is possible that some mild PD cases may not have qualified for the reimbursement of drug costs. To validate PD diagnosis in the register, a sample (nϭ126) of certificates used for PD drug reimbursement was re-evaluated retrospectively by a neurologist following the diagnostic criteria supported by the National Institute of Neurological Disorders and Stroke; 80% of originally identified PD cases in the register met the criteria. 13 The Social Insurance Institution Register database can be linked to the database of health surveys using the unique personal identity number assigned to all citizens in Finland.
Covariates
A self-administered questionnaire was sent to all of the participants for completion at home. The questionnaire included information on sociodemographics, medical history, physical activity, smoking, and consumption of alcohol, coffee, and tea. Education was measured as the total years of formal schooling and was divided into birth-cohort specific tertiles. Leisure time physical activity was classified into low, moderate, or high level of activity. 8 Smoking habits were classified as never, ex-, and current smoking. Since the questions on alcohol consumption used in the first 2 surveys differed from those in the latter surveys, participants were dichotomized into abstainers and users of alcohol. We categorized coffee consumption as 0, 1 to 4, and Ն5 cups per day and tea drinking as 0, 1 to 2, and Ն3 cups per day. 14 BMI was calculated as measured weight (in kilograms) divided by height (in meters) squared. Peripheral blood samples were taken after at least a 4-hour fast. Total serum cholesterol was determined in the central laboratory at the Finnish National Public Health Institute. 10, 11 
Statistical Analysis
Differences in baseline characteristics of participants by sex and hypertensive status were examined using ANOVA or 2 test, adjusting for age and study year. Cox proportional hazards models were used to estimate the hazards ratio (HR) and 95% CI of PD associated with BP status, with follow-up time being the time scale. The follow-up time was calculated from the date of survey to the date of PD diagnosis, death, or December 31, 2006. We classified BP following the guidelines of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, 15 with minor modifications: instead of Ͻ120/ 80 mm Hg, a BP level of Ͻ130/80 mm Hg was considered normal, because only 12.0% of all participants (6.4% men and 17.1% women) had BP levels Ͻ120/80 mm Hg with no use of antihypertensive agents. Thus, all of the subjects were categorized into having normal BP (Ͻ130/80 mm Hg), high-normal BP (130 to 139/80 to 89 mm Hg), and hypertension (Ն140/90 mm Hg or use of antihypertensive drugs). In the analysis of BP components, we classified systolic pressure into Ͻ130, 130 to 139, and Ն140 mm Hg; diastolic pressure Ͻ80, 80 to 89, and Ն90 mm Hg; and pulse pressure (quartiles) Ͻ45, 45 to 53, 54 to 63, and Ն64 mm Hg. We tested statistical interaction by simultaneously including the independent variables and their cross-product term in the same model. Results were adjusted for age, sex, and study year in model 1, and in model 2, additional adjustment was made for education, BMI, smoking, alcohol consumption, physical activity, diabetes mellitus, total cholesterol, consumption of coffee and tea, and use of antihypertensive agents. The main analyses were done in the whole sample and by sex. In secondary analyses, data were stratified by age groups, diabetes mellitus, BMI, or smoking status. Finally, we performed sensitivity analyses to assess possible effects of selective survival, use of neuroleptics, and vascular or secondary parkinsonism. The PASW Statistics 18.0 for Windows (IBM SPSS Inc) was used for all of the statistical analyses.
Results
At baseline, the mean age of all of the participants was 45.0 years (SD: 11.7 years; median: 45.0 years), 96.8% were Ͻ65.0 years of age, and 51.8% were women. There were significant sex differences in all of the baseline characteristics but age (Table 1) . Furthermore, all of the characteristics were significantly associated with hypertensive status in both sexes (for online Data Supplement Table S1 , please see http:// hyper.ahajournals.org). Compared with women, men had a higher prevalence of hypertension (62.5% versus 48.8%; PϽ0.001) and a smaller proportion of normal BP (13.9% versus 28.0%; PϽ0.001), but the prevalence of high-normal BP was comparable between men and women (23.6% versus 23.2%; Pϭ0.278).
During a mean follow-up period of 18.8 years (SD: 10.2 years), 423 men and 371 women were ascertained to have developed incident PD. The mean age at PD diagnosis was 66.6 years (SD: 11.0 years) for all cases, 66.3 years (SD: 11.4 years) for male cases, and 66.8 years (SD: 10.6 years) for female cases.
Adjusting for age, sex, and study year, high-normal BP and hypertension, as compared with normotensive subjects (Ͻ130/80 mm Hg), were marginally or significantly associated with an increased HR of PD (Table 2 , model 1); these associations were no longer significant when adjusting for additional potential confounders (model 2). There were no significant associations of systolic pressure, diastolic pressure, or pulse pressure with the risk of PD in the whole sample.
There was a tendency of interaction of sex with high-normal BP (P interaction ϭ0.12) and with hypertension (P interaction ϭ0.11) on PD. We performed sex-stratifying analysis to verify whether the association of BP with PD varied by sex. In women, high-normal BP and hypertension were significantly associated with a Ͼ60% increased risk for PD after adjusting for all of the potential confounders, whereas in men there was no significant association of hypertensive status with PD (Table 3) . Overall, none of the BP components was significantly associated with the risk of PD in either sex.
Of all of the participants, 6099 (10.2%) took antihypertensives at baseline (9.5% in men; 10.9% in women). The multivariable-adjusted HR of PD associated with the use of antihypertensive agents was 1.05 (95% CI: 0.84 to 1.30) in all of the participants, 1.08 (95% CI: 0.79 to 1.48) in men, and 1.03 (95% CI: 0.76 to 1.38) in women. We further explored whether the use of antihypertensives could modify the association of hypertension with PD by dividing subjects according to their BP level and use of drugs. In women, untreated (BP Ն140/90 mm Hg and no use of antihypertensive agents), Values are meanϮSD or n (%). *P value is for the test of difference between men and women, adjusted for age and study year. We explored the possible effect of postmenopausal status on the association of BP with PD by examining the statistical interaction of age (Ն55 versus Ͻ55 years) with BP status. There was no statistical interaction of age with hypertensive status on PD risk (PϾ0.59 for all interaction terms). However, the interactions of BP components with age were statistically or marginally significant for systolic pressure of 130 to 139 mm Hg (P interaction ϭ0.02) or Ն140 mm Hg (P interaction ϭ0.06) and for diastolic pressure Ն90 mm Hg (P interaction ϭ0.09). Analysis stratifying by age suggested that an elevated systolic pressure among women aged Ն55 years or an increased diastolic pressure among women aged Ͻ55 years was significantly or marginally associated with an increased HR of PD (Table 4 ). In men, there was no statistical interaction between age and BP status on PD risk (PϾ0.20 for all interaction terms), and analysis stratifying by age groups did not reveal any significant association between BP and the risk of PD (Table S2 ).
We reported previously that diabetes mellitus and BMI Ն23 kg/m 2 were associated with an increased risk of PD. 10, 11 In this analysis of enlarged cohorts, we could verify our previous reports: the multivariable-adjusted HRs of PD associated with diabetes mellitus were 1.57 (95% CI: 1.06 to 2.34) in all of the participants, 1.51 (95% CI: 0.89 to 2.54) in men, and 1.60 (95% CI: 0.87 to 2.93) in women; the corresponding figures associated with BMI Ն23 versus Ͻ23 kg/m 2 were 1.63 (95% CI: 1.29 to 2.06), 1.90 (95% CI: 1.33 to 2.70), and 1.43 (95% CI: 1.04 to 1.96). We found no statistical interaction of hypertensive status with diabetes mellitus or with increased BMI (PϾ0.46 for all interaction terms) on the risk of PD in either men or women. Finally, compared with never smoking, the multivariable-adjusted HRs of PD associated with former and current smoking were 1.01 (95% CI: 0.82 to 1.24) and 0.68 (95% CI: 0.55 to 0.83) in all participants, 0.97 (95% CI: 0.77 to 1.22) and 0.66 (95% CI: 0.52 to 0.85) in men, and 1.00 (95% CI: 0.61 to 1.62) and 0.74 (95% CI: 0.50 to 1.10) in women. There was no interaction of hypertensive status with smoking on PD risk in either sex (PϾ0.42 for all interaction terms). Further analyses stratifying by BMI, diabetes mellitus, or smoking did not reveal any significant association between BP status and the risk of PD in either stratum.
We performed sensitivity analyses to verify the main results in women. First, to evaluate the influence of selective survival and the possible effect of preclinical PD on BP, we excluded subjects who were diagnosed with PD or who died during the first 5-year follow-up period (nϭ424). The multivariable-adjusted HRs of PD associated with highnormal BP and hypertension were 1.96 (95% CI: 1.21 to 3.17) and 1.98 (95% CI: 1.25 to 3.14). Second, to assess the influence of vascular parkinsonism, we excluded subjects who were diagnosed with stroke or who died of stroke during the follow-up period (nϭ1860). The corresponding HRs were 1.56 (95% CI: 1.01 to 2.40) and 1.53 (95% CI: 1.02 to 2.32). Third, when subjects who took neuroleptics at baseline or during the follow-up period (nϭ1165) were excluded, the corresponding HRs for PD were 1.59 (95% CI: 0.99 to 2.56) and 1.75 (95% CI: 1.12 to 2.74). Finally, when subjects either taking neuroleptics or having developed stroke (nϭ2907) were excluded from the analytic sample, the multivariableadjusted HRs of PD associated with high-normal BP and hypertension were 1.41 (95% CI: 0.87 to 2.30) and 1.62 (95% CI: 1.02 to 2.55). Similar sensitivity analyses in men did not reveal any significant association of PD with hypertensive status (data not shown).
Discussion
In this large-scale population-based prospective study of Finnish men and women, we found that, in women, compared with normotensive subjects, high-normal BP and hypertension are associated with a Ͼ60% increased risk of PD. Furthermore, above-optimal diastolic pressure in women aged Ͻ55 years and elevated systolic pressure in women aged Ն55 years are associated with an increased risk of PD. These associations are less likely attributable to vascular or secondary parkinsonism. In men, however, PD is not associated with BP or hypertension. We found no evidence that the use of antihypertensive agents is associated with the risk of PD.
The association of PD with high-normal BP may partly reflect the effect of hypertension because a considerable proportion of people with BP levels of 130 to 139/80 to 89 mm Hg are likely to have progressed to hypertension during the long-term follow-up period. 15 The finding of high-normal BP in association with PD in women (88% aged Ͻ60 years at baseline) also echoes the findings of the Honolulu-Asia Aging Study of Japanese-American men for dementia, in which midlife prehypertension was associated with an increased risk of dementia. 16 The sex-specific association with PD has been reported for other cardiovascular risk factors, such as hypercholesterolemia. 5 Interestingly, we found that increased diastolic pressure among young adult women and elevated systolic pressure in women aged Ն55 years were associated with an increased risk of PD. This is in line with the fact that, for cardiovascular risk, there is a trend toward a decline in the relative importance of diastolic pressure and an increase in the importance of systolic pressure with HR indicates hazard ratio. *Model 1 was adjusted for age, study year, and, if applicable, diastolic or systolic pressure; in Model 2, additional adjustment was made for education, smoking, alcohol consumption, body mass index, physical inactivity, diabetes mellitus, consumption of coffee and tea, total cholesterol, and, if applicable, the use of antihypertensive agents.
advancing age. 17 Worth noting is that systolic pressure increases progressively with age, whereas diastolic pressure remains constant, or even declines, after the fifth and sixth decades of life. Thus, elevated systolic pressure is fairly common in elderly people. In particular, alteration in estrogen levels over the perimenopausal period can cause systolic hypertension in women. 18 All of these factors may contribute to the age-and sex-specific associations of PD with BP components. Furthermore, the sex differences in the prevalence of hypertension and in the mean age of people with hypertension (Table  S1 ) may also play a part in the sex-specific association of PD with hypertensive status. Previously, the Nurses' Health Study and Health Professionals Follow-Up Study found no association of a self-reported history of hypertension with the risk of PD 5 ; however, the misclassification of hypertension because of the inaccuracy of self-reported data may have diminished existing associations. In addition, high-normal BP, a condition that is associated with the risk of PD in our study, was not separated from normotensive BP in all previous studies. Finally, because BP may decline with the onset of PD because of the autonomic dysfunction of the aging brain, and because neurogenic orthostatic hypotension is common in patients with PD, 19 the use of prevalent PD cases and the ambiguous exposure time because of retrospective assessment of the exposure are likely to account for the association of hypertension with the decreased odds ratio of PD in some case-control studies. 6, 7 The potential neuroprotective effect of antihypertensive agents on PD has been suggested for specific medications such as centrally acting L-type calcium-channel blockers. 6, 20 We found no association between the use of antihypertensive agents and the risk of PD, which is in line with previous reports from case-control and population-based prospective studies. 5, 7, 21 In addition, in women, untreated hypertension or treated but not well-controlled hypertension is associated with an increased risk of PD. Unfortunately, we are not able to conclude whether controlling BP at an optimal target level will diminish the increased risk of PD associated with elevated BP because of the small number of subjects in this group. Finally, diabetes mellitus and obesity often concurrently occur with hypertension, but we found no evidence that the association of hypertension and high-normal BP with the risk of PD varied by these conditions. Cerebrovascular disease and the use of certain drugs (eg, neuroleptics) may cause vascular or secondary parkinsonism. However, this concern has been partly addressed in the sensitivity analyses, which indicate that the association of high-normal BP and hypertension with PD in women is less likely attributed to secondary or vascular parkinsonism. It is noteworthy that the associations of high-normal BP and hypertension with the risk of PD in women were slightly attenuated when stroke patients in follow-up were excluded from the analysis. However, this attenuation may represent an underestimation of the true associations, because patients with PD have an increased risk of developing comorbid cerebrovascular disease. 22 Pathologically, PD is characterized by a severe loss of dopaminergic neurons that is visible as depigmentation of the substantia nigra pars compacta in the basal ganglia. Given that the pathogenesis leading to the selective death of dopaminergic neurons is poorly understood, 1,2 the biological mechanisms linking hypertensive status to PD can only be speculative. First, long-standing elevated BP can cause ischemic cerebrovascular lesions. Clinicopathological studies suggest that cerebral microvascular diseases (eg, white-matter lesions and cerebral amyloid angiopathy) are likely to contribute to the clinical expression and deterioration of idiopathic PD symptomatology. 23, 24 Therefore, hypertension and elevated BP can be linked to PD by affecting the nondopaminergic subcortical structures. Second, chronic high BP causes hypertensive vasculopathy in the basal ganglia, thalamus, and brain stem, 25 which may affect dopaminergic cells in the pars compacta and break the connections between neurons in the substantia nigra and the putamen portion of the striatum. Third, oxidative stress and renin-angiotensin system are common mechanisms leading to both hypertension and PD, especially in postmenopausal women, 26 -28 which may mediate their association. Finally, experimental research suggests that cerebral ischemia caused by long-standing hypertension may decrease the expression of ␤-2 and ␣-4 subunits of nicotinic acetylcholine receptors, which could activate the dopaminergic pathway. 29 
Strengths and Limitations
The major strengths of our study include the large cohorts of men and women from the general population and the longterm follow-up period. Thus, the statistical power is sufficient, even for subgroup analyses by sex and age. Our study also has limitations. First, some vascular parkinsonism cases may have been classified as having PD because of a lack of neuroimaging and postmortem data, although sensitivity analyses indicate that such a possibility is likely to be minimal. Furthermore, people with hypertension are more likely than normotensive people to seek healthcare services and, thus, to be ascertained to have PD. However, there is no evidence suggesting that this might introduce significant bias, because high-normal BP, which was considered normal at the time of the surveys, is also associated with the increased risk of PD. Third, the procedure of BP measurement may lead to nondifferential misclassification of hypertensive status, which is likely to result in an overestimation of the true association. Finally, although multiple potential confounders have been adjusted for, we cannot completely rule out the residual confounding attributed to a lack of repeated measurements of time-varying covariates, the inaccurate measurement of confounders, or some unmeasured confounders.
Perspectives
Optimal BP control is known to significantly reduce the risk of cardiovascular disease and possibly of Alzheimer disease. This population-based prospective study provides evidence that the risk of PD is increased among women with highnormal BP and hypertension, especially when left untreated or uncontrolled. These findings indicate that optimal control of BP and related vascular morbidity in young-and middleaged women may potentially reduce the risk of PD. Given the high prevalence of high-normal BP and hypertension (72% for both conditions combined in women) and their moder-ately strong association with PD, the impact on public health of effective interventions for the optimal control of BP is likely to be huge. 
